scholarly journals Bone mineral accrual in 4- to 10-year-old precompetitive, recreational gymnasts: A 4-year longitudinal study

2011 ◽  
Vol 26 (6) ◽  
pp. 1313-1320 ◽  
Author(s):  
Marta C Erlandson ◽  
Saija A Kontulainen ◽  
Phil D Chilibeck ◽  
Catherine M Arnold ◽  
Adam DG Baxter-Jones
1998 ◽  
Vol 133 (5) ◽  
pp. 682-687 ◽  
Author(s):  
Heather A. McKay ◽  
Donald A. Bailey ◽  
Robert L. Mirwald ◽  
K.Shawn Davison ◽  
Robert A. Faulkner

Bone ◽  
2008 ◽  
Vol 43 (6) ◽  
pp. 1101-1107 ◽  
Author(s):  
Adam D.G. Baxter-Jones ◽  
Saija A. Kontulainen ◽  
Robert A. Faulkner ◽  
Donald A. Bailey

2006 ◽  
Vol 17 (7) ◽  
pp. 1043-1054 ◽  
Author(s):  
B. L. Matthews ◽  
K. L. Bennell ◽  
H. A. McKay ◽  
K. M. Khan ◽  
A. D. G. Baxter-Jones ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (10) ◽  
pp. e107759 ◽  
Author(s):  
Donvina Vaitkeviciute ◽  
Evelin Lätt ◽  
Jarek Mäestu ◽  
Toivo Jürimäe ◽  
Meeli Saar ◽  
...  

Bone ◽  
2007 ◽  
Vol 40 (6) ◽  
pp. S25 ◽  
Author(s):  
A.D. Baxter-Jones ◽  
R.A. Faulkner ◽  
R.L. Mirwald ◽  
D.A. Bailey

Bone ◽  
2007 ◽  
Vol 40 (5) ◽  
pp. 1196-1202 ◽  
Author(s):  
Qingju Wang ◽  
Markku Alén ◽  
Patrick Nicholson ◽  
Harri Suominen ◽  
Arvo Koistinen ◽  
...  

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1195.2-1195
Author(s):  
K. Pavelka ◽  
L. Šenolt ◽  
O. Sleglova ◽  
J. Baloun ◽  
O. Růžičková

Background:Hand osteoarthritis (OA) and its more severe subset erosive hand OA are common causes of pain and morbidity. Some metabolic factors were suggested to be implicated in erosive disease. Few studies investigated differences in systemic bone loss between erosive and non-erosive hand OA.Objectives:To compare the change of bone mineral density (BMD) between patients with erosive and non-erosive hand OA in a two-year longitudinal study.Methods:Consecutive patients with symptomatic HOA fulfilling the American College of Rheumatology (ACR) criteria were included in this study. Erosive hand OA was defined by at least one erosive interphalangeal joint. All patients underwent clinical assessments of joint swelling and radiographs of both hands. DEXA examination of lumbar spine, total femur and femur neck was performed at the baseline and after two years.Results:Altogether, 141patients (15 male) with symptomatic nodal HOA were included in this study and followed between April 2012 and January 2019. Out of these patients, 80 had erosive disease after two years. The disease duration (p<0.01) was significantly higher in patients with erosive compared with non-erosive disease at baseline.Osteoporosis (T-score <-2.5 SD) was diagnosed in 12.5% (9/72) of patients with erosive hand OA and in 8.06% (5/57) of patients with non-erosive hand OA at baseline. BMD was significantly lowered in patients with erosive compared with non-erosive disease at baseline (lumbar spine: 1.05g/cm2 vs. 1.13 g/cm2, p<0.05, total femur: 0.90 g/cm2 vs. 0.97 g/cm2, p<0.01 and femur neck: 0.86 g/cm2 vs. 0.91, p<0.05). T-scores of lumbar spine (-0.96 vs. -0.41 SD, p<0.05), total femur (-0.69 vs. -0.33 SD, p<0.05) and femur neck (-1.14 vs. -0.88 SD, p<0.05) were also significantly lowered in patients with erosive compared with non-erosive disease.Two years, the BMD remained also significantly lowered in patients with erosive compared with non-erosive disease (lumbar spine: 1.05g/cm2 vs. 1.14 g/cm2, p<0.05, total femur: 0.92 g/cm2 vs. 0.97 g/cm2, p<0.05 and femur neck: 0.86 g/cm2 vs. 0.91, p<0.05), which was in agreement with the finding for T-scores of lumbar spine (-1.05 vs. -0.39 SD, p<0.05), total femur (-0.74 vs. -0.34 SD, p<0.01) and femur neck (-1.07 vs. -0.72 SD, p<0.01).Conclusion:These results suggest that patients with erosive hand OA are at higher risk for the development of general bone loss. Over two years patients with erosive disease had significant lower bone mineral density at all measured sites.References:[1]This work was supported by the project AZV no. 18-00542 and MHCR No. 023728.Acknowledgments:Project AZV no. 18-00542 and MHCR No. 023728Disclosure of Interests:Karel Pavelka Consultant of: Abbvie, MSD, BMS, Egis, Roche, UCB, Medac, Pfizer, Biogen, Speakers bureau: Abbvie, MSD, BMS, Egis, Roche, UCB, Medac, Pfizer, Biogen, Ladislav Šenolt: None declared, Olga Sleglova: None declared, Jiří Baloun: None declared, Olga Růžičková: None declared


Bone ◽  
2007 ◽  
Vol 41 (5) ◽  
pp. 903-905 ◽  
Author(s):  
Moira A. Petit ◽  
Julie M. Hughes ◽  
Rachel J. Wetzsteon ◽  
Susan A. Novotny ◽  
Meghan Warren

Sign in / Sign up

Export Citation Format

Share Document